News

Feb. 15. 2022

Sawai Receives Approvals for Seven Generic Drugs with 14 Strengths

Dec. 09. 2021

Sawai Announces Listing of Five Generic Drugs with Nine Strengths

Dec. 03. 2021

Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-

Aug. 16. 2021

Sawai Receives Approvals for Four Generic Drugs with Eight Strengths

Jun. 17. 2021

Sawai Launches Eight Generic Drugs with 23 Strengths

Apr. 01. 2021

Notice of Establishment of Sawai Group Holdings

Feb. 15. 2021

Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths

Feb. 12. 2021

Sawai Reports Third Quarter FY2020 Financial Results

Jan. 28. 2021

Sawai and Neurolief enter into Exclusive Development and Marketing Agreement for Relivion

Dec. 16. 2020

Upsher-Smith Launches Ramelteon Tablets

Dec. 10. 2020

Sawai Launches Two Generic Drugs with 10 Strengths

Nov. 24. 2020

Notice of Convocation of an Extraordinary General Meeting of Shareholders and the Matters to be Resolved Thereat, as well as Partial Amendments to the Articles of Incorporation

Nov. 09. 2020

Sawai Reports First Half of FY2020 Financial Results

Oct. 19. 2020

Sawai Launches Dutasteride Capsules

Oct. 06. 2020

Sawai Receives Approval for Dutasteride Capsules

Aug. 17. 2020

Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths

Aug. 11. 2020

Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection

Aug. 06. 2020

Sawai Reports First Quarter FY2020 Financial Results

Jul. 28. 2020

Notice of Transition to a Holding Company Structure through Sole-Share Transfer and Establishment of the Record Date for Convocation of an Extraordinary General Meeting of Shareholders

Jul. 02. 2020

Upsher-Smith Launches Propafenone Hydrochloride Extended-Release Capsules

Jun. 25. 2020

Upsher-Smith Launches Ethacrynic Acid Tablets, USP

Jun. 23. 2020

Sawai Launches Vardenafil Tablets

Jun. 22. 2020

Sawai and Neugen Pharma enter into Co-development and Definitive License Agreement for ALS Drug

Jun. 18. 2020

Sawai Launches 14 Generic Drugs with 29 Strengths